Trial Condition(s):

Renal anemia

BAY85-3934, Liver impairment study

Bayer Identifier:

14634

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2013-003944-22

EU CT Number:

Not Available

Study Completed

Trial Purpose

The study was conducted in a single-center, non-randomized, non-controlled, nonblinded, observational design with group stratification.

Inclusion Criteria

- Male and female white subjects aged between 18 to 79 years with a body mass index (BMI) of 18 to 34 kg/m2;
- Subjects with hepatic impairment Child Pugh A or B with documented liver cirrhosis confirmed by histopathology, e.g., previous liver biopsy, laparoscopy, ultrasound, or fibroscan;
- Age, weight and gender matched healthy subjects (mean age and body weight in the control group and in the 2 groups with hepatic impairment were not to vary by more than ± 10 years and ± 10 kg).

Exclusion Criteria

No Exclusion Criteria Available

Trial Summary

Enrollment Goal

Trial Dates

January2014

September2014

Phase

Could I receive a placebo?

Products

Musredo (Molidustat, BAY85-3934)

Accepts Healthy Volunteers

Where to Participate

Locations

Locations
Locations Investigative Site Kiel, Germany, 24105	Contact Us: E-mail: [email protected] Phone: Not Available

Investigative Site

Kiel, Germany, 24105

Contact Us:

E-mail: [email protected]

Phone: Not Available

Renal anemia

Bayer Identifier:

ClinicalTrials.gov Identifier:

EudraCT Number:

EU CT Number:

Trial Purpose

Key Participation Requirements

sex

age

18 Years

79 Years

Inclusion Criteria

Exclusion Criteria

Inclusion Criteria

Exclusion Criteria

Trial Summary

Enrollment Goal

Trial Dates

Phase

Could I receive a placebo?

Products

Accepts Healthy Volunteers

Where to Participate

For details, please refer to trial results

Additional Information